Literature DB >> 10528663

Dyslipidaemia and the progression of renal disease in chronic renal failure patients.

Z A Massy1, T Nguyen Khoa, B Lacour, B Descamps-Latscha, N K Man, P Jungers.   

Abstract

BACKGROUND: Dyslipidaemia is common in patients with chronic renal failure (CRF), and there is increasing evidence to support the role of dyslipidaemia as a contributing factor in the progression of chronic renal disease. However, few prospective studies have been carried out which address the possible relationship between dyslipidaemia and the rate of progression of renal disease in patients with renal failure.
METHODS: Between January 1985 and December 1997, we prospectively assessed the risk of CRF progression to dialysis in a cohort of 138 patients. Forty CRF patients reached end-stage renal disease (ESRD) and had to start supportive therapy during the follow-up period [group ESRD(+)]. The remaining 98 CRF patients served as controls [group ESRD(-)]. Potential clinical and laboratory risk factors for more rapid CRF decline to dialysis, including lipid abnormalities and baseline creatinine clearance were determined at the start of the follow-up period.
RESULTS: Several significant differences were found in univariate analysis between the two groups of CRF, ESRD(+) and ESRD(-), namely a shorter follow-up period, a lower level of baseline creatinine clearance, a faster rate of creatinine clearance decline, a higher level of serum triglycerides, fibrinogen, total homocyst(e)ine and proteinuria, and a lower level of serum high-density lipoprotein in the ESRD(+) group than in the ESRD(-) group. However, by multivariate Cox analysis proteinuria [relative risk (95% confidence interval) 1.32 (1.16-1.50) for each g/day P = 0.001], baseline creatinine clearance [0.53 (0.40-0.70) for each 10 ml/min, P = 0.001] and chronic interstitial nephritis and hypertensive nephrosclerosis [0.38 (0.17-0.84) for presence, P = 0.005] were the only significant risk factors for CRF progression to dialysis. Hypertriglyceridaemia and male gender were selected in the final model, but were of borderline significance.
CONCLUSIONS: These results suggest a limited role for dyslipidaemia in the progression of chronic renal disease to dialysis in CRF patients, in contrast with the powerful influence of proteinuria, baseline creatinine clearance and nephropathy type in predicting this progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528663     DOI: 10.1093/ndt/14.10.2392

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Statin use is associated with prolonged survival of renal transplant recipients.

Authors:  Franz Wiesbauer; Georg Heinze; Christa Mitterbauer; Franz Harnoncourt; Walter H Hörl; Rainer Oberbauer
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

3.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

4.  Does the KDIGO CKD risk stratification based on GFR and proteinuria predict kidney graft failure?

Authors:  Cristina Bucşa; Gabriel Stefan; Dorina Tacu; Ioanel Sinescu; Ruxandra Diana Sinescu; Mihai Hârza
Journal:  Int Urol Nephrol       Date:  2014-06-20       Impact factor: 2.370

5.  Hypertriglyceridemia accompanied by increased serum complement component 3 and proteinuria in non-nephrotic chronic kidney disease.

Authors:  Kentaro Kohagura; Masako Kochi; Tsuyoshi Miyagi; Takanori Kinjyo; Yuichi Maehara; Kojiro Kinjyo; Kazufumi Nagahama; Atsushi Sakima; Kunitoshi Iseki; Yusuke Ohya
Journal:  Clin Exp Nephrol       Date:  2013-06-12       Impact factor: 2.801

6.  Progression of kidney disease in type 2 diabetes - beyond blood pressure control: an observational study.

Authors:  David J Leehey; Holly J Kramer; Tarek M Daoud; Maninder P Chatha; Majd A Isreb
Journal:  BMC Nephrol       Date:  2005-06-28       Impact factor: 2.388

7.  Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study.

Authors:  Asahi Hishida; Kenji Wakai; Mariko Naito; Shino Suma; Tae Sasakabe; Nobuyuki Hamajima; Satoyo Hosono; Mikako Horita; Tanvir Chowdhury Turin; Sadao Suzuki; Tara Sefanya Kairupan; Haruo Mikami; Keizo Ohnaka; Isao Watanabe; Hirokazu Uemura; Michiaki Kubo; Hideo Tanaka
Journal:  Lipids Health Dis       Date:  2014-10-14       Impact factor: 3.876

8.  HDL Cholesterol Level Is Associated with Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing PCI.

Authors:  Hoon Suk Park; Chan Joon Kim; Byung-Hee Hwang; Tae-Hoon Kim; Yoon Seok Koh; Hun-Jun Park; Sung-Ho Her; Sung Won Jang; Chul-Soo Park; Jong Min Lee; Hee-Yeol Kim; Doo Soo Jeon; Pum-Joon Kim; Ki-Dong Yoo; Kiyuk Chang; Dong Chan Jin; Ki-Bae Seung
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

9.  A clinical study about contrast nephropathy: risk factors and the role of beta blockers.

Authors:  Çağdaş Akgüllü; Ufuk Eryılmaz; Hasan Güngör; Ahmet Huyut; Cemil Zencir; Tolga Hekim
Journal:  Anatol J Cardiol       Date:  2014-04-28       Impact factor: 1.596

10.  Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus.

Authors:  Lluís Guirado; Dolores Burgos; Carme Cantarell; Ana Fernández; Antonio Franco; Miguel Ángel Gentil; Auxiliadora Mazuecos; Josep Vicenç Torregrosa; Ernesto Gómez Huertas; Juan Carlos Ruiz; Jaime Sánchez Plumed; Javier Paul; Ricardo Lauzurica; Sofía Zárraga; Antonio Osuna; Carlos Jiménez; Ángel Alonso; Alberto Rodríguez; Beatriz Bardají; Domingo Hernández
Journal:  Transplant Direct       Date:  2015-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.